<DOC>
	<DOCNO>NCT02055989</DOCNO>
	<brief_summary>This study phase I/II dose escalation trial design test feasibility deliver IMRT thyroid , larynx hypopharynx cancer patient , assess safety possible improvement outcome dose increase . This protocol fact two study run parallel : thyroid cancer patient larynx/ hypopharynx cancer patient . These two group patient treat differently analyse separately . The primary objective Phase I sequential cohort study determine feasibility deliver modest acceleration dose-escalated IMRT locally advance high-risk thyroid cancer . We report incidence prevalence acute toxicities 2 dose fractionation regimen . DL1 : primary site 58.8 Gy 28 daily fraction nodal level 50 Gy 28 daily fraction DL2 : primary 66.6 Gy 30 daily fraction post operative nodal level 60 Gy 30 daily fraction elective nodal level 54 Gy 30 daily fraction</brief_summary>
	<brief_title>A Phase I/II Study Use Intensity Modulated Radiotherapy ( IMRT ) Cancer Thyroid , Larynx Hypopharynx</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>1 . Newly diagnose histologically confirm squamous cell undifferentiated carcinoma head neck . 2 . Newly diagnose histologically confirm papillary , follicular , undifferentiated medullary carcinoma thyroid . 3 . Tumours arise oral larynx hypopharynx require radical radiation primary tumour parallel oppose lateral field , bilateral cervical lymph node irradiation . 4 . High risk radiation induce xerostomia conventional radiotherapy due irradiation majority parotid gland ( define estimate mean dose parotid gland great 26 Gy use conventional radiotherapy technique ) . 5 . Radiotherapy either primary therapy postoperative ( thyroid carcinoma ) . Techniques detail centre . Neoadjuvant concomitant chemotherapy permit . 6 . Stage T14 , N13 , M0 disease 7 . Zubrod Performance Status 02 1 . Previous radiotherapy head neck region 2 . Previous malignancy except nonmelanoma skin cancer 3 . Previous concurrent illness investigator opinion would interfere either completion therapy followup 4 . Prophylactic use amifostine pilocarpine allow 5 . Brachytherapy allow part treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>